RxDoctor Payments Data

Henry Cheng, MD

Cardiovascular Disease · Chattanooga, TNNPI 1669748638

Payments from drug & device makers

$5,376in general payments, 2019–2025

Across 228 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$843
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$795
  • Amgen$550
  • Novartis$491
  • Elutia, Inc.$381
  • Alnylam Pharmaceuticals Inc.$375
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,376 in reported general payments places this provider in the 65th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$186,078
Medicare patients
2,146
Services billed
3,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis133$2,967,183
VyndaqelTafamidis Meglumine31$673,247
EliquisApixaban188$200,718
EntrestoSacubitril/Valsartan72$73,092
JardianceEmpagliflozin37$42,481
XareltoRivaroxaban44$40,438
Rosuvastatin Calcium168$3,151
Nebivolol Hcl37$3,094
Prasugrel Hcl13$2,582
Carvedilol228$1,861
Metoprolol Succinate118$1,759
Atorvastatin Calcium146$1,712
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$1,661
Losartan Potassium151$1,343
Amiodarone Hcl21$1,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$148$3,841,148352 claims
NovartisEntresto$491$73,09272 claims
Boehringer IngelheimJardiance$84$42,48137 claims
Johnson & JohnsonXarelto$231$40,43844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →